Compare Ascendis Pharma A/S (ASND) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Noble Corporation plc — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Noble Corporation plc trades at $41.01 (market cap $6.38B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Noble Corporation plc's market cap, and Noble Corporation plc pays a 5% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NE | |
|---|---|---|
Market Cap | $17.74B | $6.38B |
Sector | Health | Technology |
52-Week High | $277.18 | $54.37 |
52-Week Low | $163.32 | $25.70 |
Enterprise Value | $18.11B | $7.63B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Noble Corporation (NE) trades at $39.97, up 2.75% today, with a bearish technical signal and mixed quarterly earnings. The company maintains solid cash flow, with $228M net cash flow in 2025, and recently secured a three-well UKCS contract from BP. Valuation metrics show a P/E of 27.95 and EV/EBITDA of 7.2, while analyst consensus is divided with a $50 price target.
Outlook is cautious due to recent earnings misses and bearish technicals, but strong operational cash flow and new contracts offer stability. Risks include execution challenges and oil market volatility, while the dividend and low leverage provide shareholder support. Investors should weigh fundamental strength against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
